Batten Disease (BD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

This reports provides a data-driven overview of the current and future competitive landscape in BD therapeutics.

Across the 16 major pharmaceutical markets, the analyst estimates that there are 8,537 diagnosed prevalent cases of BD in 2023 and the number is expected to increase to 8,717 cases by 2028.

The marketed space for BD treatment is limited only to BioMarin's Brineura (cerliponase alfa).
There is a lack of late-stage pipeline drugs for BD; only seven drugs are currently in Phase II globally.

15 trials have been initiated or planned in BD, five of which have been completed, while seven trials are currently ongoing. Of the seven ongoing trials, approximately 71.4% are in Phase I/II, and 28.6% are in Phase I of development, while no trials are in Phase III development.

Partnership is the most prevalent deal type in Europe (71.4%).

Scope

The analyst's BD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts

Reasons to Buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the BD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.